Trevi Therapeutics initiated its Phase 3 OCEAN-2 trial for IPF-related chronic cough and continues recruiting in all three active trials, including a Phase 2 dose-ranging trial for non-IPF ILD-related chronic cough expected to start in early 2027. The company received a patent allowance for nalbuphine ER dosing in hepatically impaired patients and ended Q3 2026 with $299.4 million in cash, funding operations into 2030. R&D expenses rose due to clinical trial activities, and the net loss widened to $21.5 million for the quarter. Trevi aims to address significant unmet needs in chronic cough with no current FDA-approved therapies and plans to report key trial results through 2027 and 2028.
Trevi Therapeutics reported a net loss of $21.5 million for Q3 2026, alongside ongoing clinical trials and a strong cash position of $299.4 million as of November 10, 2026. For readers following the Health sector, here is Pluang's market snapshot as of Nov 10, 2026 04:11 WIB: out of 150 priced US Health stocks, 125 rose and 23 fell. Notable movers include HIMS at USD 21.66 with a -16.69% change and 100% buy order activity, ARWR at USD 49.30 down 15.23%, and IMVT at USD 35.11 up 15.00% with nearly balanced buy/sell activity.
AmpliTech Group, a company specializing in RF and microwave components for telecom and defense, will announce its third quarter 2026 financial results on November 12, 2026, after market close. The company will host a conference call at 5:00 PM ET the...
Toll Brothers has announced the grand opening of new luxury single-story model homes at Hidden Vista, a gated community in Palm Desert, California, on November 14. These homes offer up to 2,700 sq ft with 3-4 bedrooms, modern open floor plans, and pr...
FocusReactive, a web development agency specializing in Next.js and headless CMS, achieved top rankings across six major industry review platforms in 2026, including Clutch, DesignRush, and The Manifest. The agency was recognized globally for experti...
Indonesia's e-commerce market is projected to grow from $120.2 billion in 2027 to $239.4 billion by 2032, with a CAGR of 14.78%. Growth is fueled by rising mobile commerce adoption, live-stream shopping, digital payment solutions like PayLater, and e...
Security National Financial Corporation reported a 38.6% drop in after-tax earnings for Q3 2026, falling to $6.17 million due to challenging mortgage market conditions and increased interest rates. The mortgage segment faced a $2.65 million loss driv...
